Chest Radiation: Another Sweet Spot for Transcatheter Aortic Valve Replacement
Anthony A. Bavry, MD, MPH

The growth of transcatheter aortic valve replacement (TAVR) for the management of severe aortic stenosis continues to expand.1 This procedure was initially approved in 2011 for use in inoperable patients.2 Through careful study, TAVR has subsequently been evaluated in high-risk,3 intermediate-risk,4 and, finally, low-risk patients,5,6 although approval for use has not yet been granted for the latter category. Because study and/or approval of TAVR now encompasses patients across the entire risk spectrum, the role of surgical aortic valve replacement (SAVR) needs to be reevaluated.

It is currently appropriate to consider SAVR for patients who require another surgical procedure in addition to aortic valve replacement.7 Examples would be complex multivessel coronary artery disease that requires coronary artery bypass grafting or an ascending aortic aneurysm that requires aortic root replacement. However, multivessel coronary artery disease with a low SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score (ie, focal stenoses) can be treated with percutaneous coronary intervention with good result.8

Among young patients (eg, <59 years) who require aortic valve replacement and can tolerate anticoagulation therapy, the choice of a durable mechanical valve may be appropriate.7 However, a proportion of young patients are not appropriate for anticoagulation therapy for a variety of reasons; therefore, a tissue valve will still need to be considered. In these patients, it is debatable whether a surgical valve with a proven long-term track record would be preferred instead of a transcatheter valve with more limited follow-up data. Although transcatheter valves are thought to have better hemodynamics and a lower incidence of patient prosthesis mismatch than surgical valves,9 the PARTNER 3 (Placement of Aortic Transcatheter Valve) low-risk trial found that surgical valves were associated with a slightly lower mean aortic gradient and a slightly larger aortic valve area at 30 days and 1 year compared with transcatheter valves.5

Potential acute and long-term concerns that need to be considered with a transcatheter valve in a young patient include (1) valve deterioration, (2) paravalvular aortic regurgitation, and (3) need for a permanent pacemaker. Regarding the first issue, there has been some concern about TAVR leaflet thrombosis10; however, to date, with intermediate follow-up, this does not appear to be a significant clinical problem.11 With current-generation devices, the rate of moderate to severe aortic regurgitation is quite low in a tricuspid aortic valve (0.8% with a balloon-expandable valve and 3.5% with a self-expanding valve).5,6 The need for a permanent pacemaker is also low for a balloon-expandable valve (6.5%)9 but remains high for a self-expanding valve (17.4%).

Bicuspid aortic valves are frequently encountered among younger patients. These valves are often associated with higher eccentricity, extreme annular calcification, calcified raphe, and large size, which can increase the risk of moderate to severe paravalvular aortic regurgitation and thus compromise the long-term efficacy of valve replacement. Adverse valve characteristics can also increase the risk of annular rupture. Bicuspid aortic valves have been associated with more frequent conversion to surgery and lower device success.12 Early generation balloon-expandable valves (eg, Sapien XT; Edwards Lifesciences) have been associated with higher rates of annular rupture and aortic root injury, whereas early generation self-expanding valves (ie, CoreValve; Medtronic) have been associated with higher rates of second valve implantation and moderate to severe paravalvular leak in bicuspid aortic versus tricuspid aortic valves.12,13 However, no difference in these outcomes has been observed for bicuspid versus tricuspid valves with new-generation valves.12 Accordingly, a careful assessment of the bicuspid valve/annular complex by TAVR-protocol computed tomography and echocardiography is mandatory among patients with a

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Department of Medicine, University of Florida, Gainesville, FL.

Correspondence to: Anthony A. Bavry, MD, MPH, North Florida/South Georgia Veterans Health System (Malcom Randall Veterans Administration Medical Center), Medical Service, Cardiology Section (111D), 1601 SW Archer Road, Gainesville, FL 32608. E-mail: anthony.bavry@va.gov

J Am Heart Assoc. 2019;8:e012783. DOI: 10.1161/JAHA.119.012783.

© 2019 The Author. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

DOI: 10.1161/JAHA.119.012783
bicupid valve being considered for TAVR. In a low-risk young patient with unfavorable bicupid valve characteristics, surgery would still be preferred.

Patients with prior chest radiation represent a high-risk group with known poor outcomes from surgery. Patients with chest radiation undergoing open heart surgery have increased incidence of atrial fibrillation, stroke, and death compared with patients without chest radiation. Moreover, patients with chest radiation continue to do poorly with increased long-term mortality. TAVR has been shown to be feasible in patients with aortic stenosis and prior chest radiation with good echocardiographic and clinical outcomes.

In this issue of the Journal of the American Heart Association (JAH A), Zhang et al performed a careful and important study of patients with severe aortic stenosis and prior chest radiation. They compared outcomes of patients who underwent SAVR versus TAVR at the Mayo Clinic. Each group had 55 patients. Compared with SAVR patients, TAVR patients were sicker, as represented by a higher Society of Thoracic Surgery estimated risk for 30-day mortality (5.1% versus 1.6%, P<0.001). In the short term, TAVR was associated with a reduction in length of stay and lower incidence of atrial fibrillation compared with SAVR. The 30-day observed-to-expected mortality was lower with TAVR versus SAVR. However, readmissions were higher at 90 days, predominantly because of heart failure. Although heart failure exacerbations could have been caused by paravalvular aortic regurgitation, there was no statistical difference in this outcome at 6 months between treatment groups. This study is noteworthy because the investigators performed a careful inverse propensity-weighting analysis to compare SAVR with TAVR.

Future studies will need to address the risk of readmission among patients with aortic stenosis and chest radiation who undergo TAVR.

In summary, we continue to move into an era that provides aortic stenosis patients with more treatment options. For some patients, SAVR remains an important option for the reasons stated. For the majority of patients, TAVR is a safe, effective, and expanding treatment for aortic stenosis. Based on the results of this study, aortic stenosis patients with chest radiation represent a sweet spot for the use TAVR.

Disclosures
Dr Bavry receives honoraria from the American College of Cardiology and Edwards Lifesciences and is an advisor to Cardiovascular Systems Inc.

References
1. Grover FL, Vemulpalli S, Carroll JD, Edwards FH, Mack MJ, Thurani VH, Brindis RG, Shahian DM, Ruiz CE, Jacobs JP, Hanzel G, Bavaria JE, Tuzcu EM, Peterson ED, Fitzgerald S, Kourits M, Michaels J, Christensen B, Seward WF, Hewitt K, Holmes DR Jr; STS/ACC TVT Registry. 2016 Annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017;69:1215–1230.
2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607.
3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Bablaarios V, Vohrani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011:364:2187–2198.
4. Reardon M, Van Mieghem NM, Pompaa JJ, Kleiman NS, Sonegaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Yang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP; SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–1331.
5. Pompaa JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser J, Merhi W, Kleiman NS, Asken J, Soraja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3×0, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramblawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Giao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–1715.
6. Mack MJ, McLeon MB, Thurani VH, Makkar R, Kodal SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarat P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Bablaarios V, Goldman S, Szeto WY, Genereux P, Persaud A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695–1705.
7. Nishimura RA, Otto CM, Bonow RO, Erwin JP 3RD, Guyton S, Hoerlein BB, Arain T, Jinzaki M, Shimizu H, Fukuda K, Malenka DJ, Thourani VH, Petersen JL, Akin JJ, Anderson WN, Hewitt K, Holmes DR Jr; STS/ACC TVT Registry. 2016 Annual report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e621–e643. Erratum in: Circulation. 2014;130:e78. DOI: 10.1161/JAHA.119.012783

CW, Park SW, Kim HS, Butter C, Khalique OK, Schaefer U, Nietlispach F, Kodali SK, Leon MB, Ye J, Chevalier B, Leipsic J, Delgado V, Bax JJ, Tamburino C, Colombo A, Sandegaard L, Webb JG, Park SJ. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol. 2016;68:1195–1205.

14. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, Roselli EE, Smedira NG, Svensson LG, Griffin BP, Desai MY. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc. 2017;6:e005396. DOI:10.1161/JAHA.116.005396.

15. Dijos M, Reynaud A, Leroux L, Réant P, Cornolle C, Roudaut R, Dos Santos P, Lafitte S. Efficacy and follow-up of transcatheter aortic valve implantation in patients with radiation-induced aortic stenosis. Open Heart. 2015;2:e000252.

16. Zhang D, Guo W, Al-Hijji MA, El Sabbagh A, Lewis BR, Greason K, Sandhu GS, Eleid MF, Holmes DR, Herrmann J. Outcomes of patients with severe symptomatic aortic valve stenosis after chest radiation—transcatheter versus surgical aortic valve replacement. J Am Heart Assoc. 2019;8:e012110. DOI:10.1161/JAHA.119.012110.

**Key Words:** Editorials • aortic stenosis • radiation • transcatheter aortic valve implantation